Pfizer Ltd.
NSE: PFIZER · Pharmaceuticals
Snapshot
Unlock Pfizer Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Pfizer Limited is a pharmaceutical company engaged in the manufacturing, marketing, and export of a diverse range of medicinal products. Its portfolio spans multiple therapeutic areas, including cardiovascular, oncology, vaccines, and central nervous system treatments.
Business Model
The company generates revenue by selling pharmaceutical products through a network of independent distributors across India and international markets. It leverages its global brand presence to market a wide array of therapeutic solutions.
- Incorporation Year:1950
Growth Outlook
Growth is driven by the company's extensive therapeutic portfolio and its established distribution network. Continued focus on high-demand segments like vaccines and specialty care remains a key strategic priority.
Key Risks
- Regulatory Risk. The pharmaceutical industry is subject to stringent price controls and regulatory oversight by Indian authorities, which can impact profit margins.
- Competitive Pressure. The company faces intense competition from both domestic generic manufacturers and multinational corporations in the Indian market.
- Supply Chain Dependency. Reliance on complex global supply chains for active pharmaceutical ingredients exposes the company to potential disruptions and cost volatility.
- Intellectual Property Risk. The expiration of patents on key products may lead to increased competition from lower-cost generic alternatives.
Start your research today
Unlock AI insights, financials, peers and live data on Pfizer Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,570 Cr
TTM · standalone
NET PROFIT
₹735 Cr
TTM · standalone
EPS
₹160.70
TTM · standalone
RETURN ON EQUITY
17.5%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
23.2%
TTM · standalone
P/E
28.7x
Q1 FY27 · standalone
EV/EBITDA
19.0x
Q1 FY27 · standalone
EBITDA MARGIN
43.1%
TTM · standalone
NET PROFIT MARGIN
31.3%
Q1 FY27 · standalone
DEBT TO EQUITY
0.0x
Q1 FY27 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Pfizer Ltd.PFIZER | ₹21,088 Cr | 28.69 | 18.96 | 10.7% | 43.1% | 17.5% | 23.2% | -10.6% |
Caplin Point Laboratories Ltd.CAPLIPOINT | ₹21,365 Cr | 32.11 | 23.06 | 15.0% | 40.3% | 21.1% | 25.7% | +32.8% |
Granules India Ltd.GRANULES | ₹21,021 Cr | 31.35 | 16.73 | 24.8% | 22.8% | 15.1% | 20.1% | +65.4% |
Shilpa Medicare LimitedSHILPAMED | ₹18,857 Cr | 63.10 | 40.08 | 27.9% | 28.9% | 12.0% | 14.2% | +14.5% |
Eris Lifesciences Ltd.ERIS | ₹18,314 Cr | 28.11 | 17.93 | 9.7% | 35.5% | 19.7% | 15.5% | -25.1% |
Onesource Specialty Pharma Ltd.ONESOURCE | ₹17,630 Cr | -362.69 | 53.51 | 27.2% | 22.8% | -0.8% | 0.9% | -18.2% |
As of Q1 FY27
Financials
Pfizer Ltd.
NSE: PFIZER · Pharmaceuticals
Snapshot
Unlock Pfizer Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Pfizer Limited is a pharmaceutical company engaged in the manufacturing, marketing, and export of a diverse range of medicinal products. Its portfolio spans multiple therapeutic areas, including cardiovascular, oncology, vaccines, and central nervous system treatments.
Business Model
The company generates revenue by selling pharmaceutical products through a network of independent distributors across India and international markets. It leverages its global brand presence to market a wide array of therapeutic solutions.
- Incorporation Year:1950
Growth Outlook
Growth is driven by the company's extensive therapeutic portfolio and its established distribution network. Continued focus on high-demand segments like vaccines and specialty care remains a key strategic priority.
Key Risks
- Regulatory Risk. The pharmaceutical industry is subject to stringent price controls and regulatory oversight by Indian authorities, which can impact profit margins.
- Competitive Pressure. The company faces intense competition from both domestic generic manufacturers and multinational corporations in the Indian market.
- Supply Chain Dependency. Reliance on complex global supply chains for active pharmaceutical ingredients exposes the company to potential disruptions and cost volatility.
- Intellectual Property Risk. The expiration of patents on key products may lead to increased competition from lower-cost generic alternatives.
Start your research today
Unlock AI insights, financials, peers and live data on Pfizer Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,570 Cr
TTM · standalone
NET PROFIT
₹735 Cr
TTM · standalone
EPS
₹160.70
TTM · standalone
RETURN ON EQUITY
17.5%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
23.2%
TTM · standalone
P/E
28.7x
Q1 FY27 · standalone
EV/EBITDA
19.0x
Q1 FY27 · standalone
EBITDA MARGIN
43.1%
TTM · standalone
NET PROFIT MARGIN
31.3%
Q1 FY27 · standalone
DEBT TO EQUITY
0.0x
Q1 FY27 · standalone
Peers · Pharmaceuticals
As of Q1 FY27